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reasons [3]. The HIV-1 RNA concentration 
(viral load) is an important predictor of the 
HIV transmission level through sexual in-
tercourse, needle sharing, or from mother 
to infant [3]. The CD4 cell count is the most 
important predictor of patient survival when 
starting antiretroviral (ART) HIV therapy. 
In patients with lower CD4 cell counts, the 
immune deficiency may be irreversible and 
early treatment shows more benefits when 
compared to delayed treatment [4].
In 2009, the WHO recommended new regi-
mens for ART treatments and recommended 
ART treatment for adults and adolescents 
with early stage disease [5,6]. These revised 
ART treatment guidelines also recommended 
ART treatment for all adults and adolescents, 
including HIV-infected pregnant women, 
IntroductIon
According to a 2014 report by the World 
Health Organization (WHO), 35 million pe-
ople are infected worldwide with the human 
immunodeficiency virus (HIV) [1]. In 2013, 
2.1 million people were newly infected, with 
the number of deaths related to acquired im-
mune deficiency syndrome (AIDS) about 1.5 
million [1]. In Turkey, according to Ministry 
of Health data published in 2013, more than 
6000 people were infected with HIV [2]. The 
numbers of new cases in 2010, 2010, and 
2013 (the first 6 months) in the same report 
were 589, 1,068, and 587, respectively [2].
HIV transmission includes heterosexual in-
tercourse, homosexual/bisexual intercourse, 
intravenous drug use, nosocomial transmis-
sion, vertical transmission, and unknown 
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AbstrAct
OBJECTIVE: Infection with the human immunodeficiency virus (HIV), the causative agent of acquired immune deficiency 
syndrome (AIDS), is a major global health problem. Patients with HIV can live normal lives with today’s new treatment 
options. As the treatment is generally successful, the life expectancy of patients infected with HIV is rising. As a result, the 
economic burden of HIV treatment on health systems is set to increase. According to the Ministry of Health, there were 
more than 6000 HIV-positive patients in Turkey in 2013. The aim of this study was to determine the direct costs of HIV 
treatment in Turkey.
METHOD: A retrospective data analysis was performed from the reimbursement agency perspective. Data for 252 patients 
at a university hospital in Ankara from 2001 to 2012 were used for the analysis. The average costs of treatment per HIV 
patient and the average costs per HIV patient, depending on the state of the patient’s health, were calculated. The latter was 
determined according to the number of CD4 cells/ml, as defined by the CDC’s classification system for HIV infection. The 
cost of treatment was calculated based on published reimbursement prices in 2013, per patient per year.
RESULTS: The CD4 values of 25.3%, 29%, and 45.7% of the 252 patients were <100 cells/mm3, 100–300 cells/mm3, and 
>300 cells/mm3, respectively. The treatment costs per patient per year for 2013 for those with CD4 values of <100 cells/
mm3, 100–300 cells/mm3, and >300+ cells/mm3 were $ 5,637.04, $ 2,211.54, and $ 2,182.35, respectively. The weighted 
average of the treatment cost per patient was $ 3,344.64 for 2013.
CONCLUSION: This analysis is unique to Turkey and calculates the cost only of HIV treatment in Turkey. Lower CD4 
values are associated with higher treatment costs. Appropriate HIV treatment is crucial for controlling CD4 values and 
lowering the treatment costs of HIV patients. These findings need to be considered by policy makers who may need to 
focus on HIV. 
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with a CD4 count of < 350 cells/mm3, re-
gardless of clinical symptoms [5]. While the 
WHO’s 2009 guidelines were outdated, the 
newly published guidelines recommend tre-
atment as soon as possible [6].
According to data from a cost-effectiveness 
study in sub-Saharan Africa, HIV preven-
tion was 28 times more cost-effective than 
highly active ART treatment (HAART) [7]. 
According to that study, each 1 year of life 
acquired by HAART equaled to 28 years 
of life acquired by prevention. In the meta-
analysis of Creese et al. [8], there were gross 
differences between interventions in terms 
of cost-effectiveness. Furthermore aiming at 
condom dispensation in treatment of sexual-
ly-transmitted diseases and selective blood 
safety measurements led to $ 11 cost for each 
prevented HIV patient, and 1 DALY (lost life 
year) was gained for each 1 $ [8].
Today in Turkey diagnostic methods and 
ART treatment are provided free of charge 
to HIV patients as part of a national insuran-
ce system [9]. However, no previous studies 
have reported the disease- and treatment-re-
lated costs of HIV in Turkey. The main goal 
of the present study was to determine the tre-
atment costs of HIV patients in Turkey.
MAterIAls And Methods
Data collection
To obtain data for the cost analysis, patient 
files of a university hospital in Ankara were 
retrospectively evaluated. The university 
hospital in Ankara was one of the first HIV 
clinics in Turkey and is a reference center 
for the entire country. Within a 12-year fol-
low-up period (2001-2012) in the university 
hospital, 252 patients allocated, and data in-
cluded polyclinic, clinic, intervention, labo-
ratory and imaging tests, medications, side 
effects, comorbidities, treatments, and com-
plications.
Classification of the patient groups
The HIV patients were classified according 
to their CD4 cell counts (cell/mm3). Group 1 
consisted of patients with CD4 cell counts of 
<100 cells/mm3, Group 2 consisted of those 
with cell counts of 100–300 cells/mm3, and 
Group 3 consisted of those with cell counts 
of >300 cells/mm3. Patient distribution of the 
university hospital was used as the generali-
zation of estimation of expert opinions (Ta-
ble I).
Health service-related 
cost calculations
In the analysis, the total cost of hospital ou-
tpatient clinics was calculated by using gyne-
cology, infectious disease, psychiatry, neu-
rology, dermatology, physical therapy and 
rehabilitation, emergency medicine, internal 
diseases/endocrinology visits, percent of pa-
tients in visits, number of visits per patient, 
and cost of visit. Cost of tests were calcula-
ted by using percent patients requiring test, 
number of tests per patient, and cost of each 
test. The cost of infection was calculated by 
using data on the number of hospitalizations 
per year, percentage of patients requiring ho-
spitalization, mean number of days of hospi-
talization, daily costs of hospitalization, and 
total costs of hospitalization. The total costs 
of complications were calculated based on 
the percentage of patients with side effects 
and treatment duration of the complications.
Clinical and intensive care hospitalization 
costs were included in the cost calculations. 
The clinical and intensive care hospitaliza-
tion costs were calculated by using the num-
ber of annual hospitalizations, percentage 
of patients requiring hospitalization, mean 
duration of the hospital stay, and daily cost 
of hospitalization. The annual number of in-
terventions, percentage of patients requiring 
interventions, number of interventions, and 
costs of interventions were used to calculate 
the total cost of intensive care interventions.
In the cost calculation, the cost of health ser-
vices was based on the 2013 prices of the 
Health Administration Notification of Social 
Security Institution. The costs obtained in 
Turkish lira were converted into U.S. dollars 
based on the mid-year exchange ratio in 2013 
of $ 1.90.
estimation of the cost per patient
The disease costs were calculated for each 
CD4 patient group. The weighted mean me-
thod and patient distribution were used to 
calculate the annual cost of HIV per capita. 
The costs of ART drugs were excluded from 
the analysis.
results
The costs of the treatment in the three groups 
and the weighted mean cost of HIV patients 
are reported in Table II. The healthcare costs 
Classification CD4 Cell Count (cell/mm3) Distribution (n. 252)
Group 1 <100 25.3%
Group 2 100–300 29%
Group 3 >300 45.7%
Table I. Classification of the patients according to their CD4 cell counts and their 
distribution
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of Group 1, 2, and 3 were $ 5,637.04, $ 
2,211.54, and $ 2,182.34, respectively. When 
these data were used to calculate the annual 
HIV weighted cost per patient, the cost was 
$ 3,344.64.
dIscussIon
In Turkey, the treatment cost of HIV/AIDS is 
not evaluated in terms of the disease burden. 
This may be due to the lower numbers of HIV 
patients compared with those in developed 
countries. However, considering reports of 
increases in the numbers of new patients in 
Turkey [2], it may be necessary to determine 
the cost of HIV to understand the burden of 
the diseases in the country.
The cost of HIV infections in the U.S. was 
estimated to be $ 36.4 billion (direct and indi-
rect costs) in 2002. Of this, $ 6.7 billion com-
prised direct treatment costs, and $ 29.7 bil-
lion comprised indirect costs. According to a 
sensitivity analysis of the cost analysis in the 
United States, universal ART utilization and 
more effective ART regimes would reduce 
the disease cost [10]. In the U.S the direct and 
indirect costs of HIV increased from $ 36.4 
billion in 2002 to $ 51.2 billion in 2009, and 
HIV was among the top 20 diseases in terms 
of disease cost [11]. Another analysis based 
on Medicaid claims in the state of California 
reported that the medical cost per patient was 
$ 36,469 [12].
The cost of HIV treatment per patient was 
estimated to be € 11,638, € 32,110, € 14,821, 
€ 6,399, and € 25,340 in Spain, Germany, 
France, Italy, and the U.K. respectively [13]. 
According to that report, there was great di-
sparity in the total medical costs for patients 
with CD4 lymphocyte counts of 200-500 
cells/mm3 [13]. For example, in Italy the total 
healthcare cost of HIV treatment per patient 
was reported to be € 19,252, € 12,227, and € 
6,399 for CD4 counts of < 200, > 200 but < 
500, and > 500, respectively [13].
According to a study conducted in the U.S. 
in 2006, adult HIV patients with a CD4 count 
higher than 350/ml who were receiving ART 
treatment had a predicted expected life expec-
tancy of 24.2 years [14]. In that study, the re-
HIV classification
Outpatient visits
($ pro capita)
laboratory 
($ pro capita)
Inpatient visits 
($ pro capita)
Complications 
($ pro capita)
Total healthcare cost 
($ pro capita)
Group 1 192.07 1,297.09 1,888.81 2,259.05 5,637.04
Group 2 82.00 760.04 306.72 1,062.78 2,211.54
Group 3 76.57 773.20 47.36 1,285.20 2,182.35
Weighted mean cost ($) 3,344.64
Table II. Total healthcare costs of HIV patients
*The costs of ART pharmaceuticals were excluded
Figure 1. Annual cost ($) per patient in the CD4 cell count classification groups
duced and unreduced life cost of these patients 
were $ 385,200 and $ 618,900, respectively. 
Of these costs, ART drugs accounted for 73%, 
hospitalization accounted for 13%, outpatient 
treatment accounted for 9%, and HIV-related 
drugs and laboratory tests accounted for 5%s. 
In patients with a CD4 count higher than 200/
µl, ART treatment led to 22.5 years of ex-
pected life. The reduced and unreduced life 
cost of these patients were calculated to be $ 
354,100 and $ 567,000, respectively.
According to a 2011 study conducted in 
22,315 patients, starting earlier ART tre-
atment of patients led to significantly in-
creased survival [15]. The primary goal of 
ART treatment is to prevent mortality and 
morbidity related to chronic HIV infection. 
According to previous research, patients with 
a CD4 cell count of < 200 cell/mm3 had hi-
gher cumulative direct HIV treatment costs 
in cases of delayed treatment when compa-
red to patients who had early treatment [16]. 
According to another study, decreased HIV 
transmission due to ART treatment might 
reduce the growth of the HIV epidemic and 
related costs [17].
The results of the analysis highlight the cost 
of HIV healthcare in Turkey. According to the 
analysis, the weighted mean healthcare cost 
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the number of new patients diagnosed with 
HIV/AIDS annually in Turkey, its social and 
economic impacts on the Turkish population 
need to be determined to understand the bur-
den of the disease. Future studies should in-
clude a greater number of hospitals and cen-
ters to reflect the national context.
The present analysis demonstrated that the 
cost of treatment rose in accordance with a 
decrease in CD4 levels, possibly pointing to 
a direct relationship between CD4 levels and 
treatment costs. Start treatment at an early 
stage prior to a fall in CD4 cell counts may 
reduce healthcare costs. These findings may 
be useful to clinicians treating HIV patients 
and decision makers charged with shaping 
future of HIV/AIDS health care policies.
of treating each HIV patient in Turkey was 
$ 3,344.64. In addition, the treatment cost of 
patients with a CD4 level of <100 cell/mm3 
was two-fold higher than that of patients with 
a CD4 level of 100-300 cell/mm3 or >300 cell/
mm3. These findings are similar to those re-
ported in the international literature [10-17].
A limitation of the present study is the study 
sample, which consisted of patients who at-
tended a university hospital. These might not 
be representative of the greater population in 
Turkey.
conclusIon
This study is the first economic analysis of 
HIV in Turkey. Given the continued rise in 
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